您当前位置: 首页  师资队伍  硕士生导师  药理学

单璐琛

发布时间:2022-05-08 发布单位:药学院

1、个人简介

单璐琛,女,博士,副研究员,硕士研究生导师。毕业于哈尔滨医科大学药理学专业,获博士学位。先后主持国家自然科学基金、广东省公益研究与能力建设专项基金、广东省卫生厅科研基金,广东省中医药局科研项目等课题。发表论文40余篇,被SCI收录论文33篇。参与申请发明专利3项。参编人卫社《药理学》数字化教材1部(编委)。

2、讲授课程

1)《药学实践》

2)《药患沟通实践》

3)《药学综合知识与技能》

4)《生物医药实验室安全知识》

3、研究方向

1)心血管药理学

2)代谢性疾病药理学

4、主要学术兼职

1中国药理学会心血管药理专业委员会委员

2广东省药理学会心血管药理专业委员会常务委员

5、代表性科研项目

1国家自然科学基金青年基金(NO. 81302776),新型药物靶标ERp57调节线粒体生物合成抗心肌缺血损伤的作用机制研究,2014.01-2016.12

2广东省公益研究与能力建设专项资金(NO. 2015A020211015),传统中药丹参素现代化开发治疗缺血性心脏病的成药性研究,2015.08-2017.07

3广东省中医药局科研课题(NO. 20122115),丹参素抗心肌缺血的作用靶点研究,2012.10-2014.10

4广东省卫生厅科研基金项目(NO. B2011164)ADTM激活NF-κB抗心肌缺血的保护作用及其机制研究,2011.01-2012.12

6、代表性论文和专著

1. Hu H, Xie C, Weng Z, Yu P, Wang Y, Shan L. Dexrazoxane Alleviated Doxorubicin-Induced Nephropathy in Rats. Pharmacology. 2022;107(3-4):206-215.

2.Xie C, Luo J, Hu H, Wang L, Yu P, Xu L, Sun Y, Wang Y, Shan L. A novel danshensu/tetramethypyrazine derivative attenuates oxidative stress-induced autophagy injury via the AMPK-mTOR-Ulk1 signaling pathway in cardiomyocytes. Exp Ther Med. 2021 Feb;21(2):118.

3. A Danshensu-Tetramethylpyrazine Conjugate DT-010 Overcomes Multidrug Resistance in Human Breast Cancer. Front Pharmacol. 2019 Jun 26;10:722.

4. Zhang X, Luo J, Huang Y, Deng H, Hu H, Yu P, Sun Y, Shan L, Wang Y. A Novel Danshensu-Tetramethylpyrazine Conjugate DT-018 Provides Cardioprotection by Preserving Mitochondrial Function Through the MEF2D/PGC-1α Pathway. Curr Pharm Des. 2018 Feb 12;23(39):6062-6070.

5. Xu B, Deng H, Zhang X, Luo J, Zhang G, Zhang Z, Wang Y, Shan L. A novel Danshensu/tetramethylpyrazine derivative induces vasorelaxation on rat aorta and exerts cardioprotection in dogs. Eur J Pharmacol. 2018 Jan 5;818:158-166. 

6. Novel Danshensu-Tetramethylpyrazine Conjugate DT-010 Provides Cardioprotection through the PGC-1α/Nrf2/HO-1 Pathway. Biol Pharm Bull. 2017 Sep 1;40(9):1490-1498.

7. Wang L, Chan JY, Zhou X, Cui G, Yan Z, Wang L, Yan R, Di L, Wang Y, Hoi MP, Shan L, Lee SM. A Novel Agent Enhances the Chemotherapeutic Efficacy of Doxorubicin in MCF-7 Breast Cancer Cells. Front Pharmacol. 2016 Aug 10;7:249.

8. Wang L, Zhang X, Chan JY, Shan L, Cui G, Cui Q, Wang Y, Li J, Chen H, Zhang Q, Yu P, Han Y, Wang Y, Lee SM. A Novel Danshensu Derivative Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer Cells. J Cell Biochem. 2016 Jan;117(1):94-105.

9. Cui G, Shan L, Guo L, Chu IK, Li G, Quan Q, Zhao Y, Chong CM, Zhang Z, Yu P, Hoi MP, Sun Y, Wang Y, Lee SM. Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy. Sci Rep. 2015 Jun 3;5:10353. 

10. Cui G, Shan L, Hung M, Lei S, Choi I, Zhang Z, Yu P, Hoi P, Wang Y, Lee SM. A novel Danshensu derivative confers cardioprotection via PI3K/Akt and Nrf2 pathways. Int J Cardiol. 2013 Sep 30;168(2):1349-59.

7、代表性专利

1王玉强,于沛,蒋杰,单璐琛,张高小,张在军,陈永红.丹参素衍生物及其制备方法和应用.发明专利申请号 201010142939.3,20104.

2王玉强,于沛,蒋杰,单璐琛,张高小,张在军,陈永红.丹参素川芎嗪衍生物及其制备方法和应用.发明专利申请号:201110086382.0,20114.PCT 国际专利申请: PCT/CN2012/ 070832,20122.

3王玉强,孙红莉,徐立朋,于沛,张高小,蒋杰,单璐琛.一种雷公藤红素衍生物及其用途.发明专利申请号:20101046812.9, 20104.

8、联系方式